NRIX News and Press, Nurix Therapeutics Inc. From 05/09/23

SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., P...

Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights specificity and potency of NX-5948 and superior cellular activity of both NX-2127 and ...

2023-04-14 13:00:16 ET Gainers: SAI.TECH Global Corporation ( SAI ) +166% . CXApp ( CXAI ) +80% . Oblong ( OBLG ) +88% . Allarity Therapeutics ( ALLR ) +57% . Marpai ( MRAI ) +33% . Eightco Holdings ( OCTO ) +34% . ...

2023-04-13 16:27:53 ET Nurix Therapeutics press release ( NASDAQ: NRIX ): Q1 GAAP EPS of -$0.75 beats by $0.13 . Revenue of $12.69M (+31.9% Y/Y) beats by $1.73M . Cash, cash equivalents and marketable securities was $325.6 million as of February 28, 2023 compar...

Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthritis and other inflammatory diseases A...

Nurix Therapeutics, Inc. (NASDAQ: NRIX) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 12.32% on the day to $10.12. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and...

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D.,...

2023-04-06 17:02:48 ET Gainers: Ramaco Resources ( METC ) +5% . Aemetis ( AMTX ) +5% . El Pollo Loco Holdings ( LOCO ) +5% . Independent Bank Corporation ( IBCP ) +2% . SMART Global Holdings ( SGH ) +2% . Losers: Nurix Th...

-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee -- FOSTER CITY, Calif. and SAN FRANCISCO, March 20, 2023 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) a...

2023-03-19 23:39:45 ET Summary NRIX announced early data at ASH last year. The company has a couple of major partnerships. They have a decent cash runway. Nurix Therapeutics ( NRIX ) works in the field of targeted protein degradation in order to attack cancer cells. ...